IFNA1 and myalgic encephalomeyelitis/chronic fatigue syndrome: The rationale for the initial open-label trials with rintatolimod in CFS/ME was based on its recognized broad antiviral and immunomodulatory properties as an inducer of interferon (IFN) [13].